EUCTR2004-002505-74-IT进行中（未招募）不适用
A 6-Month Open Label, Flexible Dosage Study to Assess the Safety and Effectiveness of PROVIGIL Modafinil Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
CEPHALON EUROPE0 个研究点目标入组 150 人开始时间: 2006年12月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.Excessive sleepiness associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome.MedDRA version: 7.0Level: LLTClassification code 10015595EUCTR2004-002505-74-ESCephalon Europe, A Division of Cephalon UK Limited150
进行中（未招募）
1 期
A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.Excessive sleepiness associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome.MedDRA version: 7.0Level: LLTClassification code 10015595EUCTR2004-002505-74-GBCephalon Europe, A Division of Cephalon UK Limited150
进行中（未招募）
不适用
A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.EUCTR2004-002505-74-CZCephalon Europe, A Division of Cephalon UK Limited150
进行中（未招募）
1 期
A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcolepsy or obstructive sleep apnea/hypopnea.Excessive sleepiness associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome.MedDRA version: 7.0Level: LLTClassification code 10015595EUCTR2004-002505-74-FICephalon Europe, A Division of Cephalon UK Limited150
进行中（未招募）
1 期
A 26-week, multi-center, open-label, flexible dose, long-term safety trial of asenapine in adolescent subjects with schizophrenia - Gemini-S26SchizophreniaEUCTR2009-018038-12-ROSchering-Plough Research Institute, a Division of Schering Corporation204